Janus Biotherapeutics Collaborating with Roche on Potential Autoimmune Disease Treatment

Janus Biotherapeutics (Janus) has entered into a collaboration with Roche to develop a small molecule toll-like receptor (TLR) inhibitor with the potential to address several autoimmune diseases – including lupus. 

TLRs are an important class of proteins that play a key role in the innate immune system.  Strong scientific evidence links aberrant TLR activation and signaling with the development of autoimmune disorders. Janus will work exclusively with Roche on TLR research and development.